A lung cancer patient with deep vein thrombosis:a case report and literature review

Chen, Yungu; Tsang, Yiu Sing; Chou, Xiaoxia; Hu, Jiong; Xia, Qing

doi:10.1186/s12885-019-5513-8

Cited by 9 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that patients with advanced lung adenocarcinoma are predisposed to DVT, and tumor grade may help identify patients with cancer who are at a high risk of DVT. 15 Compared with patients in the primary stage, advanced cancer patients have a relatively shortened clotting time and increased plasminogen activator inhibitor level, 4 which may be related to the higher risk of DVT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors and Impact on Outcomes of Lung Cancer Patients Concurrent with Deep Vein Thrombosis

Jin

et al. 2022

Cancer Control

View full text Add to dashboard Cite

Purpose Many investigations on prognostic factors in lung cancer have been conducted; however, little is known regarding the outcomes of lung cancer cases complicated by deep vein thrombosis (DVT). This study aimed to determine the risk factors and impact on outcomes of lung cancer patients concurrent with DVT. Methods Lung cancer patients who underwent lower-extremity venous ultrasound were enrolled in this study. The patients were divided into a DVT group and a non-DVT group. Demographic information, clinical characteristics, and survival were analyzed by t-test, Wilcoxon test, chi-squared test, and logistic regression analysis. Results Of the 160 enrolled lung cancer patients, DVT was detected in 30 patients. Among the DVT group, adenocarcinoma was the most common histological type (27/30, 90.00%). Lung cancer complicated with DVT was associated with advanced stage, more severe myocardial injury, and a hypercoagulable state (P < .05). Differences in driver genes between the two groups were not significant. Radiologically, lung cancer patients with DVT were more likely to present with pericardial effusion and pleural effusion than patients without DVT (P < .05). Following multivariable logistic regression analysis, advanced stage (OR 5.368, [95%CI 1.871-18.165], P = .021), NT-proBNP >300 pg/ml (OR 5.575, [95%CI 1.733-3.722], P = .018), D-dimer >5 mg/L (OR 8.449, [95%CI 4.323-18.536], P = .004), CRP >12 mg/L (OR 6.687, [95%CI 1.967-13.617], P = .010), and serum CEA >25 ng/ml (OR 4.755, [95%CI 1.358-3.123], P = .029) were independent risk factors for adenocarcinoma complicated with DVT. Finally, survival analysis revealed that the occurrence of DVT resulted in a poorer prognosis despite anticoagulant therapy (P < .05). Conclusion DVT is a potential complication in patients with lung adenocarcinoma and could represent a prognostic marker for unfavorable outcome. It is essential to screen for DVT in high-risk adenocarcinoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Guidelines regarding the use of anticoagulants in lung cancer patients vary. 15 Specific therapeutic studies are needed to determine the optimal duration and dose of anticoagulant treatment in patients with cancer-related DVT.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors and Impact on Outcomes of Lung Cancer Patients Concurrent with Deep Vein Thrombosis

Jin

et al. 2022

Cancer Control

View full text Add to dashboard Cite

show abstract

“…As the second cause of death, VTE poses a significant comorbidity in cancer patients, and a common cause of hospitalizations, thereby significantly contributing to cancer-associated health care costs [ 117 ]. Several cancers are associated with increased VTE risk, including renal carcinoma [ 118 ]; hepatocellular carcinoma [ 119 ]; lung cancer [ 120 ]; and esophageal and stomach cancer [ 112 ]. Moreover, VTE in esophageal or gastric cancer patients has been associated with decreased survival: patient survival without VTE is 18 months compared with 13.9 months with VTE [ 121 ].…”

Section: Platelets In Cancer—“double-edged Sword”?mentioning

confidence: 99%

Platelets in aging and cancer—“double-edged sword”

Faria

Andrade²,

Peppelenbosch

et al. 2020

Cancer Metastasis Rev

View full text Add to dashboard Cite

Platelets control hemostasis and play a key role in inflammation and immunity. However, platelet function may change during aging, and a role for these versatile cells in many age-related pathological processes is emerging. In addition to a well-known role in cardiovascular disease, platelet activity is now thought to contribute to cancer cell metastasis and tumor-associated venous thromboembolism (VTE) development. Worldwide, the great majority of all patients with cardiovascular disease and some with cancer receive anti-platelet therapy to reduce the risk of thrombosis. However, not only do thrombotic diseases remain a leading cause of morbidity and mortality, cancer, especially metastasis, is still the second cause of death worldwide. Understanding how platelets change during aging and how they may contribute to aging-related diseases such as cancer may contribute to steps taken along the road towards a "healthy aging" strategy. Here, we review the changes that occur in platelets during aging, and investigate how these versatile blood components contribute to cancer progression.

show abstract

“…2 Lung cancer is one of the most prevalent types of malignant tumor and the main cause of cancer-related death worldwide. [3][4][5] After the onset of VTE, the 1-year mortality rate is as high as 61%. 6 The risk of VTE in lung cancer patients can be as high as 4% to 20%.…”

Section: Introductionmentioning

confidence: 99%

Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis

Nwagha

Nweke²

2023

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Several biomarkers or risk factors have been identified and several prediction models exist. The major limitations inherent in these models include cost-ineffectiveness and lack of systematic stratification of risk factors resulting in the inclusion of clinically insignificant biomarkers in the models. This review aimed to systematically stratify the risk factors of lung cancer-associated venous thromboembolism (VTE) and determine the critical point for preemptive intervention. Methods: This systematic review was structured as per the Preferred Reporting Item for Systematic Reviews and Meta-analyses. We searched MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, and PsycINFO from the onset to June 2022. We included studies that reported the risk factors of lung cancer-associated VTE and corresponding risk estimates, irrespective of treatment status but studies were excluded if patients were on anti-VTE medications. We employed random effects models of meta-analysis and computed risk stability index and risk weight (Rw) to achieve the review objectives. The review protocol is registered with PROSPERO (CRD42022336476). Results: The clinically significant risk factors of VTE in lung cancer patients were D-dimer (odds ratio [OR] = 5.510, 95% CI = 2.6-11.7; Rw = 5.0), albumin (OR = 2.2, 95% CI = 1.0-4.8; Rw = 1.79), leukocyte (OR = 2.48, 95% CI = 1.9-3.2; Rw = 1.77), histological type (OR = 1.69 , 95% CI = 1.2-2.4; Rw = 1.3), age (OR = 1.56; Rw = 0.99), and hemoglobin (OR = 1.85, 95% CI = 1.3-2.6; Rw = 0.92). Based on the distribution of Rw across risk factors, the critical point (upper third of the upper quartile class) was 4.5 and may mark the point at which preemptive intervention should be commenced. Conclusions: Targeted screening for VTE in lung cancer patients could be patient-specific and should be based on a combination of the most significant risk factors required to meet the critical point, provided that such a combination is affordable as illustrated in the ALBAH model. Registration: The review protocol is registered with PROSPERO (ID: CRD42022336476).

show abstract

A lung cancer patient with deep vein thrombosis:a case report and literature review

Cited by 9 publications

References 25 publications

Risk Factors and Impact on Outcomes of Lung Cancer Patients Concurrent with Deep Vein Thrombosis

Risk Factors and Impact on Outcomes of Lung Cancer Patients Concurrent with Deep Vein Thrombosis

Platelets in aging and cancer—“double-edged sword”

Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis

Contact Info

Product

Resources

About